Search clinical trials for: Vemurafenib + Cobimetinib, Decitabine

Total 3268 results

Mohammed M Milhem
Genentech, Inc.

Terminated

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (ML28604)

Melanoma | Metastatic Melanoma | BRAF-mutated Metastatic Melanoma | V600EBRAF-mutated Metastatic Melanoma

United States
Center Eugene Marquis

Completed

Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis (CONVERCE)

Malignant Melanoma

France
Inova Health Care Services
Genentech, Inc.

Withdrawn

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

Stage IIIB-C Melanoma

United States
Radboud University Medical Center
The Netherlands Cancer Institute; Isala

Recruiting

Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy (COWBOY)

Melanoma, Malignant, of Soft Parts

Netherlands
Grupo Español Multidisciplinar de Melanoma
Roche Farma, S.A; Pivotal S.L.

Completed

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

Melanoma

Spain
Hoffmann-La Roche

Completed

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Malignant Melanoma

United States, Australia
Fondazione Melanoma Onlus
Roche S.p.a

Terminated

Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients (VECODUE)

Melanoma | Melanoma (Skin) | Melanoma Stage

Italy
Technische Universität Dresden

Terminated

Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases (RadioCoBRIM)

Brain Metastases | Malignant Melanoma Stage IV | BRAF V600 Mutation

Germany
Melissa Burgess, MD
Genentech, Inc.

Terminated

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases (CoBRIM-B)

Active Melanoma Brain Metastases

United States
Hoffmann-La Roche

Withdrawn

Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients

Neoplasms

United States
Dana-Farber Cancer Institute
Eli Lilly and Company

Active, not recruiting

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

Melanoma

United States
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (DETERMINE)

Glioma | Melanoma | Carcinoma, Non-Small-Cell Lung | Multiple Myeloma | Colorectal Neoplasms | Ovarian Neoplasms | Solid Tumor | Thyroid Cancer, Papillary | Thyroid Carcinoma, Anaplastic | Laryngeal Neoplasms | Erdheim-Chester Disease | Haematological Malignancy

United Kingdom
Sunnybrook Health Sciences Centre

Active, not recruiting

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Melanoma

Canada
Netherlands Working Group on Immunotherapy of Oncology
Hoffmann-La Roche; Amsterdam UMC, location VUmc; The Netherlands Cancer Institute

Terminated

Vemurafenib Plus Cobimetinib in Metastatic Melanoma (REPOSIT)

Metastatic Melanoma

Netherlands
University Hospital, Essen

Active, not recruiting

Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (ImmunoCobiVem)

Malignant Melanoma

Germany, France, Greece, Serbia
University Hospital Tuebingen

Terminated

Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC (NEO-VC)

Malignant Melanoma

Germany, France
Georgetown University
Genentech, Inc.; Melanoma Research Alliance

Terminated

The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma

Melanoma

United States
University of Arkansas

Withdrawn

A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib

Multiple Myeloma

United States
Hoffmann-La Roche

Completed

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma (coBRIM)

Malignant Melanoma

United States, Spain, Hungary, Israel, United Kingdom, Australia, Austria, Belgium, Czechia, France, Germany, Italy, Netherlands, Russian Federation, Sweden, Switzerland, Canada, New Zealand, Norway
Yana Najjar
Merck Sharp & Dohme LLC

Terminated

Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

Melanoma

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Melanoma

United States, Korea, Republic of, United Kingdom, Australia, France, Belgium, Italy, Portugal, Spain, Brazil, Canada, Russian Federation, Germany, New Zealand, Israel, Poland, Greece, Austria, Hungary, Netherlands
Hoffmann-La Roche

Completed

A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) (MELANIS)

Melanoma

France
Novartis Pharmaceuticals

Completed

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

Metastatic Melanoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

BRAF V600E Mutation Present | Papillary Craniopharyngioma

United States
Pfizer

Completed

Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US (OCEANMIST)

Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.; Exelixis

Active, not recruiting

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Melanoma | Skin Cancer

United States
Hoffmann-La Roche

Completed

A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

Metastatic Melanoma

Belgium, Poland
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genentech, Inc.

Withdrawn

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Melanoma

United States
University of Utah
Genentech, Inc.

Recruiting

Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (CONCERTO)

Chronic Myelomonocytic Leukemia (CMML)

United States
Fondazione Melanoma Onlus
Clinical Research Technology S.r.l.

Active, not recruiting

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)

Melanoma

Italy
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Single-agent Cobimetinib for Adults With Histiocytic Disorders

Histiocytic Disorders

United States
Hoffmann-La Roche

Completed

A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Metastatic Melanoma

France, Italy, Spain, Brazil, Latvia, Germany, Hungary, Switzerland
University of Arkansas
Genentech, Inc.

Recruiting

Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)

Arteriovenous Malformations (Extracranial)

United States
ImmVira Pharma Co. Ltd

Suspended

T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

Melanoma | Malignant Melanoma

United States
Carl Allen
Baylor College of Medicine; Genentech, Inc.; North American Consortium for Histiocytosis

Recruiting

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders (NACHO-COBI)

Histiocytic Sarcoma | Juvenile Xanthogranuloma | Histiocytic Disorders, Malignant | Erdheim-Chester Disease | Langerhan's Cell Histiocytosis | Rosai Dorfman Disease | Neuro-Degenerative Disease

United States
Genentech, Inc.
Blueprint Medicines Corporation

Recruiting

A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Fondazione Melanoma Onlus

Completed

Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation (VEMUPLINT)

Melanoma

Italy
Genentech, Inc.

Completed

A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants

Healthy Volunteers
Genentech, Inc.

Completed

A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

Neoplasms

United States, Spain
Genentech, Inc.

Completed

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Malignant Melanoma

United States
Hoffmann-La Roche

Completed

Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi)

Solid Tumors

United States, Spain, Germany, France, Israel, Italy, United Kingdom
Genentech, Inc.

Completed

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplasms

United States, Spain
Genentech, Inc.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage

Healthy Volunteer

United States
Melanoma Research Foundation Breakthrough Consortium
Genentech, Inc.

Terminated

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Melanoma | Metastatic Melanoma

United States
ABM Therapeutics Corporation

Active, not recruiting

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Advanced Solid Tumor | BRAF V600 Mutation

United States
Assistance Publique - Hôpitaux de Paris

Completed

Cobimetinib for BRAF-wild-type or Mutated Histiocytoses (COBRAH)

Disease or R Group Histiocytoses

France
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)

Solid Tumor | Haematological Malignancy

United Kingdom
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma

Malignant Melanoma

United States, Australia
Hoffmann-La Roche

Terminated

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Malignant Melanoma

United States, France, Australia, United Kingdom, Italy, Spain, Germany, Israel, Poland, Slovakia

3

Subscribe